NasdaqCM - Delayed Quote USD
Akebia Therapeutics, Inc. (AKBA)
Tune into live earnings calls Now streaming directly on quote pages.
2.3200
-0.0200
(-0.85%)
At close: May 6 at 4:00:01 PM EDT
2.3700
+0.05
+(2.16%)
After hours: May 6 at 7:15:47 PM EDT
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
160.18M
160.18M
194.62M
292.48M
211.65M
Cost of Revenue
63.18M
63.18M
74.15M
85.57M
150.67M
Gross Profit
97.00M
97.00M
120.47M
206.92M
60.98M
Operating Expense
147.42M
147.42M
166.55M
271.76M
325.48M
Operating Income
-50.41M
-50.41M
-46.08M
-64.85M
-264.50M
Net Non Operating Interest Income Expense
-18.18M
-18.18M
-6.03M
-15.69M
-19.94M
Other Income Expense
-811.00k
-811.00k
182.00k
-13.69M
2.41M
Pretax Income
-69.41M
-69.41M
-51.92M
-94.23M
-282.02M
Tax Provision
--
--
--
0.00
0.00
Net Income Common Stockholders
-69.41M
-69.41M
-51.92M
-94.23M
-282.02M
Diluted NI Available to Com Stockholders
-69.41M
-69.41M
-51.92M
-94.23M
-282.02M
Basic EPS
-0.22
-0.33
-0.28
-0.51
-1.70
Diluted EPS
-0.22
-0.33
-0.28
-0.51
-1.70
Basic Average Shares
203.74M
210.95M
187.47M
182.78M
165.95M
Diluted Average Shares
203.74M
210.95M
187.47M
182.78M
165.95M
Total Operating Income as Reported
-50.47M
-50.47M
-46.26M
-80.78M
-264.50M
Total Expenses
210.59M
210.59M
240.70M
357.33M
476.15M
Net Income from Continuing & Discontinued Operation
-69.41M
-69.41M
-51.92M
-94.23M
-282.02M
Normalized Income
-68.50M
-68.50M
-51.22M
-77.39M
-282.02M
Interest Income
3.32M
--
--
--
--
Interest Expense
18.18M
18.18M
6.03M
15.69M
19.94M
Net Interest Income
-18.18M
-18.18M
-6.03M
-15.69M
-19.94M
EBIT
-51.23M
-51.23M
-45.89M
-78.54M
-264.50M
EBITDA
-13.72M
-13.72M
-8.27M
-40.84M
-226.53M
Reconciled Cost of Revenue
63.18M
63.18M
74.15M
85.57M
150.67M
Reconciled Depreciation
37.50M
37.50M
37.63M
37.70M
37.97M
Net Income from Continuing Operation Net Minority Interest
-69.41M
-69.41M
-51.92M
-94.23M
-282.02M
Total Unusual Items Excluding Goodwill
-905.00k
-905.00k
-705.00k
-16.84M
0.00
Total Unusual Items
-905.00k
-905.00k
-705.00k
-16.84M
0.00
Normalized EBITDA
-12.82M
-12.82M
-7.56M
-24.00M
-226.53M
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
0.00
0.00
0.00
0.00
0.00
12/31/2021 - 3/20/2014
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
ESPR Esperion Therapeutics, Inc.
0.9755
-7.10%
AQST Aquestive Therapeutics, Inc.
2.6900
-4.95%
SCYX SCYNEXIS, Inc.
0.9411
-2.89%
IRWD Ironwood Pharmaceuticals, Inc.
0.9269
-0.09%
BCRX BioCryst Pharmaceuticals, Inc.
10.27
-6.89%
ASRT Assertio Holdings, Inc.
0.6100
+0.38%
BFRI Biofrontera Inc.
0.7130
+1.86%
KNSA Kiniksa Pharmaceuticals International, plc
26.94
-3.02%
ETON Eton Pharmaceuticals, Inc.
16.63
-2.00%
DVAX Dynavax Technologies Corporation
10.92
-3.02%